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Pericentrosomal Localization of the TIG3 Tumor
Suppressor Requires an N-Terminal Hydrophilic
Region Motif
Tiffany M. Scharadin1, Gautam Adhikary1, Kristin Shaw1, Dan J.B. Grun1, Wen Xu1 and Richard L. Eckert1,2,3
Tazarotene-induced gene 3 (TIG3) is a tumor suppressor protein that has a key role in controlling cell
proliferation. TIG3 is observed at reduced levels in epidermal squamous cell carcinoma, and the restoration of
expression in skin cancer cells reduces cell survival. TIG3 suppresses cell survival through mechanisms that
involve localization at the plasma membrane and at the centrosome. TIG3 interacts at the plasma membrane to
activate enzymes involved in keratinocyte terminal differentiation, and at the centrosome to inhibit daughter
centrosome separation during mitosis leading to cessation of cell proliferation and induction of apoptosis. An
important goal is identifying the motifs required for TIG3 localization at these intracellular sites as a method to
understand the function of TIG3 at each location. TIG3 encodes an N-terminal hydrophilic region (amino acids
1–135) and a C-terminal membrane-anchoring domain (amino acids 135–164). We show that the C-terminal
hydrophobic domain targets intact TIG3 to the plasma membrane, but when isolated as an independent element
localizes at the mitochondria. We further demonstrate that a segment of the N-terminal hydrophilic region
targets the centrosome. These studies provide important insights regarding the mechanisms that guide
subcellular localization of this keratinocyte survival regulator.
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INTRODUCTION
The TIG3 (tazarotene-induced gene 3) tumor suppressor
protein was originally discovered as a cell survival regulator
in human keratinocytes (DiSepio et al., 1998) that has
important biological actions in epidermis. TIG3 localizes to
the plasma membrane and at the centrosome in normal
keratinocytes and skin cancer cells (Sturniolo et al., 2003,
2005; Scharadin et al., 2011, 2012). The C-terminal hydro-
phobic region serves to anchor TIG3 to the cell membrane
(Deucher et al., 2000; Sturniolo et al., 2003, 2005) where it
activates transglutaminase. TIG3 localization at the centrosome
(Scharadin et al., 2011, 2012) is associated with inhibition
of daughter centrosome separation during mitosis, altered
microtubule, and organelle distribution, and cessation of cell
proliferation (Scharadin et al., 2011, 2012).
TIG3 expression is confined to cells that are undergoing
differentiation in the epidermis, and appears to be involved in
this process. Thus, TIG3 mRNA and protein levels are
reduced in hyperproliferative epidermal diseases, including
psoriasis and skin cancer (Duvic et al., 1997, 2000, 2003),
and treating psoriatic lesions with retinoid increases TIG3
levels, decreasing cell proliferation and activating
differentiation (DiSepio et al., 1998; Sturniolo et al., 2003).
In cultured keratinocytes, TIG3 reduces cell proliferation and
increases cornified envelope formation (Sturniolo et al., 2003,
2005; Jans et al., 2008). Moreover, TIG3 is expressed at
low levels in keratinocyte monolayers but at much higher
levels in differentiated keratinocytes grown as epidermal
equivalents (Jans et al., 2008). TIG3 also suppresses survival
of transformed keratinocytes through a process that involves
the activation of caspase-associated cell death (Scharadin
et al., 2011).
TIG3 displays significant homology to the H-rev107 family
of class II tumor suppressors (DiSepio et al., 1998; Huang
et al., 2000; Jiang et al., 2005; Tsai et al., 2007; Ou et al.,
2008). These proteins encode an N-terminal hydrophilic
region and a C-terminal membrane-anchoring domain
(DiSepio et al., 1998). The N-terminal domain encodes
several motifs, which are conserved among the H-rev107
family members, including the NCEHFV and LRYG regions
(Deucher et al., 2000). From a functional perspective, the
relative quantity of TIG3 that distributes to the plasma
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membrane versus the pericentrosomal location may have a
significant impact on biological outcome. Thus, an important
goal is identifying the mechanisms that control TIG3
intracellular distribution. This requires the identification
of motifs that target TIG3 to specific subcellular compart-
ments. In the present study, we identify a centrosome-
localizing motif in the N-terminal hydrophilic region and
suggest a molecular mechanism that may control subcellular
distribution.
RESULTS
C-terminal hydrophobic domain
The TIG3 protein encodes a 134 amino acid N-terminal
hydrophilic region and a 30 amino acid C-terminal hydro-
phobic domain (DiSepio et al., 1998; Deucher et al., 2000).
The C-terminal hydrophobic domain is conserved among
TIG3-related tumor suppressors (DiSepio et al., 1998). To
assess the function of this domain, adenoviruses were
constructed that encode full-length TIG3 and a mutant
lacking the C-terminal 30 amino acids (Figure 1a). TIG3 was
then expressed in epidermis-derived squamous-cell carcinoma
(SCC)-13 skin cancer cells. Consistent with an absence of
endogenous TIG3 in cancer cells, these cells do not express
TIG3 (Scharadin et al., 2011, 2012). Figure 1b shows that full-
length TIG3 (TIG31–164) distributes in a punctate manner, with
particular accumulation around the centrosome where it
colocalizes over pericentrin (yellow signal). Recent co-staining
studies show that centrosomal markers colocalize with TIG3
and that other organelle markers colocalize to a lesser extent
(Scharadin et al., 2011, 2012). In contrast, TIG31–134
distributes diffusely throughout the cytoplasm and does not
localize with pericentrin (Figure 1b).
The diffuse cytoplasmic localization corresponds
with the loss of TIG3 biological activity. SCC-13 cells were
infected with empty virus (EV), TIG31–164-, or TIG31–134-
encoding adenovirus and after 24 hours cell numbers were
determined (black bars). Figure 1c shows that the cell number
doubles in 24 hours in EV-infected cultures, but does not
increase in TIG31–164-expressing cells. In contrast, TIG31–134
does not reduce cell survival. To assay biological end
points, cell lysate was collected from cells to measure caspase
activity. Figure 1d shows that full-length TIG3 induces
caspase and polyADP-ribose polymerase (PARP) cleavage,
but this is not observed in the cells expressing TIG31–134.
These findings suggest that the C-terminal hydrophobic region
of TIG3 is important for proper TIG3 subcellular localization
and function.
We next created green fluroscent protein (GFP) fusion
proteins encoding the N-terminal or C-terminal regions of
TIG3 (Figure 2a), and examined the distribution in SCC-13
cells. Figure 2b shows that TIG31–134-EGFPN1 assumes
a cytoplasmic distribution similar to that of TIG31–134.
Interestingly, TIG3134–164-EGFPN1 distributes to a unique
intracellular location. To identify this location, TIG31–134-
EGFPN1-expressing cells were stained to detect the
mitochondria (MitoTracker), the centrosome (pericentrin), the
Golgi (GM130), and the endoplasmic reticulum (calnexin).
Figure 2c shows that TIG31–134-EGFPN1 colocalizes with
mitochondria (MitoTracker) as indicated by the yellow signal
in the merged image.
N-terminal hydrophilic region
The above studies indicate that neither the N- nor the
C-terminal regions mediate TIG3 pericentrosomal locali-
zation, suggesting that the localizing domain may be masked.
We therefore generated a series of N-terminal hydrophilic
domain–EGFPN1 fusion mutants to identify the pericen-
trosomal localization motif (Figure 3a). The TIG329–134,
TIG348–134, and TIG3110–134 mutants distribute in the cyto-
plasm (Figure 3b), similar to the distribution of TIG31–134
(Figure 1b). However, similar to the full-length TIG3
(Figure 1b), TIG375–134, TIG384–134, TIG393–134, TIG3102–134,
and TIG3102–125 concentrate at a perinuclear location, sug-
gesting that a centrosome localization signal exists within
TIG3 amino acids 102–125 (Figure 3b). This is supported
by the finding that truncation of the N-terminus (TIG3110–134)
or the C-terminus (TIG375–110, TIG3102–119) results in loss
of pericentrosomal localization (Figure 3b). TIG3-GFP fusion
mutant–expressing cells were co-stained to detect pericentrin,
a centrosome protein (Scharadin et al., 2011, 2012). The
TIG375–134, TIG384–134, TIG393–134, TIG3102–134, and TIG3102–
125 fusion proteins colocalize with the pericentrin signal, but
the other mutants do not (Figure 3b). As previously reported
(Scharadin et al., 2011, 2012), co-staining with anti-GM130, a
Golgi marker, revealed minimal TIG3 colocalization with
TIG3 (not shown). Figure 3c shows that the TIG3 mutant
proteins are expressed and that there is no correlation between
expression level and centrosome localization, suggesting that
the localization pattern is not an artifact related to the
expression level.
The adjacent panel in Figure 3c shows wild-type TIG3
expression in cells, illustrating the fact that wild-type TIG3 is
much smaller than the TIG3-EGFPN1 fusion proteins used in
this experiment because of the size (27 kDa) of EGFPN1.
We were concerned that the fusion of EGFPN1 to the TIG3
mutants may influence subcellular distribution. We therefore
examined the location of selected TIG3-FLAG fusion proteins
(Figure 4a). The FLAG tag adds only a small number of amino
acids. Analysis of the TIG375–134-, TIG384–134-, TIG393–134-,
and TIG3102–134-FLAG fusion proteins in SCC-13 cells reveals
a perinuclear distribution, as evidenced by colocalization with
pericentrin (yellow), consistent with that observed for the
EGFPN1 fusion proteins (Figure 4b). These findings indicate
that a specific TIG3 motif targets pericentrosomal localization
of TIG3. We also confirmed that the centrosome-localizing
motif operates in other epidermis-derived cells by showing
that the TIG3102–125-FLAG fusion protein localizes at the
centrosome in A431 cells and in normal human foreskin
keratinocytes (Figure 4C).
We also assessed whether these constructs are function-
ally active. We transfected SCC-13 cells with each
FLAG-tagged TIG3-mutant shown in Figure 4a and b
and after 48 hours co-stained the cells with anti-FLAG and
anti-cleaved PARP. PARP cleavage is an end point of
TIG3 action (Scharadin et al., 2011, 2012). Only one
mutant, TIG375–134-FLAG retained residual ability to
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Figure 1. TIG3 C-terminal domain is required for appropriate intracellular localization and function. (a) Tazarotene-induced gene 3 (TIG3) protein domain
structure. Purple indicates the N-terminal hydrophilic region and green indicates the C-terminal hydrophobic region. Regions of the protein that are conserved in
other H-rev107 family members are shown in orange. The N-terminal homology domain, and the NCEHFV and LRYG motifs are shown (Deucher et al., 2000).
(b) Subcellular localization of TIG31–164 and TIG1–134. SCC-13 cells were infected with 10 multiplicity of infection (MOI) TIG31–164 or 50 MOI TIG31–134 adenovirus
and after 24hours the cells were fixed and stained with anti-TIG3 and appropriate secondary antibody (green). The sections were also stained with anti-pericentrin
and appropriate secondary antibody (red). The yellow signal indicates colocalization of TIG3 and pericentrin, red indicates the absence of colocalization. Arrows
indicate the centrosomes. Bars¼ 10mm. (c) Impact of full-length TIG31–164 and TIG31–134 on cell survival. Cells were infected with 10 MOI of empty (EV) and
TIG31–164- and TIG31–134-encoding adenoviruses and at 24hour postinfection the cells were harvested for cell count. The open bar indicates cell number at the time
of virus delivery (t¼ 0) and the shaded bars indicate cell numbers 24hours later. The values are mean±SEM. Single asterisk indicates a significant increase in cell
number (n¼ 3, Po0.05) as compared with the control, whereas the double asterisk indicates reduced cell number compared with the other 24-hour data points
(n¼ 3, Po0.05) as determined by the Student’s t-test. (d) Impact of TIG31–164 and TIG31–134 on SCC-13 cell apoptosis. SCC-13 cells were infected with the indicated
adenovirus and after 24hours the cells were harvested for assay of caspase and polyADP-ribose polymerase (PARP) status. The arrows indicate TIG3 monomers and
the bracket indicates high-molecular-weight cross-linked TIG3, as previously described (Sturniolo et al., 2003, 2005; Jans et al., 2008; Eckert et al., 2009).
Figure 2. Role of the C- and N-terminal domains in guiding subcellular localization. (a) Schematic of TIG3-EGFPN1 fusion proteins. The proteins are as
described in Figure 1a, and the blue rectangle designates EGFPN1. (b) Subcellular localization of TIG31–134-EGFPN1 and TIG3134–164-EGFPN1 in SCC-13 cells.
SCC-13 cells were electroporated with 3mg of the indicated plasmid and after 24 hours EGFPN1 fluorescence was detected by confocal microscopy. The arrows
indicate the novel subcellular distribution of TIG3134–164-EGPN1. No signal was observed in non-electroporated cells (not shown). (c) TIG3134–164-EGFPN1
localizes at the mitochondria. Cells were electroporated with 3mg of TIG3134–164-EGFPN1 and after 24 hours the cells were fixed and either stained with
anti-pericentrin (centrosome), GM130 (Golgi), or calnexin (endoplasmic reticulum (ER)), or incubated with MitoTracker (mitochondria) (red). The images were then
visualized by confocal microscopy. The merged images are the composite of the green and red channels, and yellow indicates colocalization. Arrows indicate
perinuclear TIG3 localization. Red, green (EGFPN1), and merged channels are shown. Bars¼ 10mm.
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stimulate PARP cleavage (an indicator of apoptosis)
(Scharadin et al., 2011, 2012). In each of the three
experiments 10, 12, and 14% of TIG375–134-FLAG-positive
cells were PARP cleavage-positive (not shown). On
the basis of these findings, we conclude that the TIG3
region responsible for centrosome localization, amino acids
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102–125, does not include the TIG3 domains required to
activate cell death.
Conserved elements required for TIG3 centrosomal localization
These findings suggest that TIG3 amino acids 102 and 125 are
sufficient for TIG3 localization at the centrosome. Within this
region are three conserved elements including the NCEHFV
and LRYG motifs and a conserved Y (DiSepio et al., 1998)
(Figure 5a). To determine the role of these motifs in TIG3
localization to the centrosome, we tested the impact of
specific mutations in each motif. Figure 5a shows the
authentic sequence (top) and each mutated sequence. Expres-
sion studies reveal that many of these mutants localize in the
cytoplasm (Figure 5b). Although none of the mutants distribute
at the centrosome, one mutant, N112F/C113G, localizes at
the mitochondria (Figure 5c). Figure 5d confirms that each
mutant is expressed. These findings indicate that all conserved
motifs, present between amino acids 102 and 125, are
required for pericentrosomal TIG3 localization.
DISCUSSION
TIG3 (Tazarotene-induced gene 3) was originally identified as
being expressed in keratinocytes treated with the anti-psoriasis
drug, tazarotene (DiSepio et al., 1998), and subsequently
identified in other tissues (Huang et al., 2000; Shyu et al.,
2005; Ou et al., 2008; Uyama et al., 2009a, 2009b). TIG3
belongs to the NIpC/P60 superfamily of proteins that share
homology with lecithin:retinol acyltransferase (LRAT) and
the H-rev107 tumor suppressor family (Hajnal et al., 1994;
Husmann et al., 1998; Anantharaman and Aravind, 2003;
Jahng et al., 2003). The 164 amino acid TIG3 protein includes
N-terminal hydrophilic and C-terminal hydrophobic regions.
The C-terminal domain, amino acids 135–164, acts as a
membrane anchor (DiSepio et al., 1998; Deucher et al.,
2000). The N-terminal domain, amino acids 1–134, encodes
a hydrophilic domain that includes conserved motifs (Uyama
et al., 2009a, b; Han et al., 2010).
TIG3 subcellular distribution
TIG3 accumulates at the cell membrane and at the centro-
some in SCC-13 cells and in normal keratinocytes. Membrane
association permits TIG3 interaction with type I transglutami-
nase (Sturniolo et al., 2003, 2005; Jans et al., 2008), which
leads to increased type I transglutaminase expression and
activity resulting in enhanced cornified envelope formation
(Sturniolo et al., 2003, 2005). The C-terminal membrane-
anchoring domain of TIG3 is required for this activity, and
C-terminus-deleted TIG3 redistributes to the cytoplasm and is
inactive (Sturniolo et al., 2003, 2005; Jans et al., 2008).
TIG3 also distributes to a perinuclear localization in normal
and transformed keratinocytes (Scharadin et al., 2011), and
staining with organelle markers indicates that the centrosome
and the surrounding area is the major site of localization
(Scharadin et al., 2011, 2012). The centrosome is a key con-
troller of cell structure, mitosis, and intracellular transport
(Doxsey et al., 2005; Soldati and Schliwa, 2006; Lim et al.,
2009), and serves to structure microtubules in interphase cells
during cell division (Schliwa and Woehlke, 2003; Doxsey
et al., 2005). Centrosome accumulation of TIG3 causes
redistribution of the microtubules, increased microtubule sta-
bility, altered microtubule growth, and inhibition of daughter
centrosome separation during cell division (Scharadin et al.,
2011, 2012).
Identifying motifs that control TIG3 subcellular location
Our goal in this study is to identify motifs that drive organelle-
specific TIG3 localization. We show that deletion of the
C-terminal hydrophobic region results in TIG3 localization
in the cytoplasm. This is consistent with our previous
reports (Deucher et al., 2000; Sturniolo et al., 2003, 2005;
Jans et al., 2008; Eckert et al., 2009) and the reports of others
(Sers et al., 1997; Akiyama et al., 1999; Scharadin et al.,
2011). We also show that the isolated TIG3 hydrophobic
region targets the mitochondria. This is an unexpected, but
potentially important observation. Full-length TIG3 drives
differentiation of normal human keratinocytes (Sturniolo
et al., 2003, 2005; Jans et al., 2008; Eckert et al., 2009),
but TIG3 mutants lacking the amino terminus are pro-
apoptotic. Moreover, the apoptotic activity increases as the
TIG3 N-terminus is shortened (Jans et al., 2008). This would
predict that the C-terminus may be involved in apoptosis.
Our present study, showing that this region targets the
mitochondria, is consistent with a pro-apoptotic role of the
C-terminus. Understanding the implications of this interesting
observation will require additional study.
The TIG3 N-terminal region
The function of the TIG3 N-terminal hydrophilic region is not
well understood. It has been reported to encode phospholi-
pase A2 activity (Jahng et al., 2003; Han et al., 2010);
however, it is not likely that this activity is required for TIG3
anti-cancer function, as we have shown that mutants encoding
only the N-terminal hydrophilic region of TIG3 accumulate in
the cytoplasm and have no biological activity. The fact that
the TIG3 C-terminal domain localizes at the mitochondria
suggests that the centrosome localization domain must reside
within the N-terminus. To assess this possibility, we
constructed a series of TIG3-GFP fusion proteins in which
various lengths of the N-terminal hydrophilic region was
linked to EGFPN1. Truncation experiments identify a region
spanning amino acids 102–125 that is a minimal region
required for centrosome localization. Centrosome localization
of this region was confirmed using TIG3102–125-EGFPN1 and
TIG3102–125-FLAG fusion proteins. This region also prompted
pericentrosomal localization in A431 skin cancer cells and
normal human keratinocytes, indicating that the centrosome-
localizing function operates in multiple cell types. This region
is conserved among TIG3 and other related members of the
H-rev107 protein family (Deucher et al., 2000). There is a
conserved motif at amino acid position 102 (Q102) that is part
of the centrosome localization motif (Figure 5a). The
highly conserved NCEHFV and LRYG motifs are also
contained within this region (Figure 5a) (Deucher et al.,
2000). In addition, two conserved Y residues (amino acids
106 and 122) are present (Deucher et al., 2000). Systematic
mutation of these amino acids suggests that each of these
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Figure 3. Presence of putative centrosome localization signal in the TIG3 N-terminal hydrophilic region. (a) Schematic showing the TIG3 fusion proteins in
which segments of the TIG3 N-terminal hydrophilic region are fused to EGFPN1 (blue). The TIG3 domains are as described in Figure 1a. (b) Subcellular distribution of
fusion proteins. SCC-13 cells were electroporated with 3mg of each indicated plasmid and after 24 hours the EGFPN1 signal was detected by confocal microscopy
(green) and pericentrin was detected with anti-pericentrin and appropriate secondary antibody (red). Colocalization of TIG3 mutant and pericentrin is indicated by the
yellow signal (arrows). TIG375–134, TIG384–134, TIG393–134, TIG3102–134, and TIG3102–125 colocalize with pericentrin at a pericentrosomal location (arrows).
Bars¼ 10mm. (c) Expression level of TIG3-EGFPN1 fusion proteins. SCC-13 cells were transfected with 3mg of each construct and after 24hours the cells were
harvested and cell extract was prepared and incubated with anti-green fluroscent protein (GFP) and appropriate secondary antibody (left panel). As a comparison,
SCC-13 cells were infected with 10 MOI of tAd5-TIG3 adenovirus and after 24hours extracts were prepared for electrophoresis and detection with anti-TIG3 (right
panel). An arrow indicates the TIG3 monomer and the brackets indicate cross-linked forms of TIG3 (Sturniolo et al., 2003, 2005; Jans et al., 2008; Eckert et al., 2009).
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conserved elements is required for TIG3 targeting to the
centrosome.
We also examined the ability of the TIG3 centrosome-
localizing motif mutants to activate apoptosis. This analysis
revealed that TIG384–134-FLAG, TIG393–134-FLAG, TIG3102–134-
FLAG, and TIG3102–125-FLAG are inactive, but that
TIG375–125-FLAG retains minimal activity. Thus, amino acids
102–125 of TIG3 specify localization to the centrosome, but
lack the protein domains required to drive cell death or
differentiation. This indicates that other elements in the protein
encode the death domains (Scharadin et al., 2011, 2012).
Mechanism of TIG3 intracellular targeting
The 3D structure of the N-terminal hydrophilic region of
H-rev107, which shares homology with TIG3, has been
determined (DiSepio et al., 1998; Ren et al., 2010a, 2010b).
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Figure 4. Subcellular localization of TIG3-FLAG fusion proteins. (a) Schematic of the fusion proteins in which the segments of the N-terminal hydrophilic region
are fused to FLAG epitope. The TIG3 domains are described in the legend to Figure 1a. (b) SCC-13 cells were electroporated with 3mg of each TIG3-FLAG
fusion protein and after 24 hours the cells were fixed and co-stained with the centrosome marker, pericentrin (green), and Cy3-conjugated anti-FLAG antibody
(red). Each of these fusion proteins localizes at the centrosome (yellow, arrows). Bars¼ 10mm. (c) TIG3(102–125)-FLAG accumulates at the centrosome in A431
cells and normal foreskin keratinocytes (KERn). Cells were electroporated with plasmid encoding TIG3(102–125)-FLAG and then stained with antibodies as
indicated above. Bars¼ 10mm.
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Assuming similar structures, the TIG3 centrosome localization
motif corresponds to the b6-sheet and a3-helix of H-rev107
(Ren et al., 2010a, b). A key question is whether this structure
can help explain our localization results. The amino acid
102–125 motif that we show is required for TIG3 localization
to the centrosome, spans the b-sheet and a-helix segments at
the N-terminal hydrophilic region immediately upstream of
the hydrophobic tail. We suggest that the TIG3 subcellular
distribution depends on protein conformation and that the
TIG3 C-terminal hydrophobic domain may cover the b6-sheet/
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Figure 5. Detailed analysis of the centrosome localization motif. (a) Role of highly conserved amino acids in the centrosome localization motif. pTIG375–134-
EGFPN1 encodes amino acids 75–134 of TIG3 fused to the N-terminus of EGFPN1. This plasmid was used as a substrate to generate plasmids encoding the
indicated mutated sequences. Conserved sequences are indicated in red and mutated sequences are underlined in red. The distribution of TIG3102–125-EGFPN1 is
shown in Figure 3b. (b) SCC-13 cells were electroporated with 3mg of each plasmid and after 24 hours the cells were fixed and imaged by confocal microscopy.
One of the mutants, N112F/C113G, localizes with punctate structures (arrow), whereas the others distribute throughout the cytosol. TIG3 mutant staining (anti-
FLAG) is green and anti-pericentrin staining is red. Bars¼10mm. (c) The N112F/C113G mutant distributes to the mitochondria. SCC-13 cells, expressing the
N112F/C113G mutant (green), were incubated with MitoTracker dye to stain mitochondria (red) and imaged by confocal microscopy. The arrows show
localization of the N112F/C113G mutant and the yellow color in the merged image indicates colocalization of this mutant with MitoTracker. Bars¼10mm.
(d) Expression of the mutant proteins. Cells were transfected with 3mg of each plasmid and after 24 hours lysates were prepared for immunoblot detection of each
mutant using anti-GFP antibody. Similar results were observed in each of the three experiments.
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a3-helix region to reduce TIG3 interaction at the centrosome.
We further propose that moving this domain aside, via an
unknown mechanism, may uncover the b6-sheet/a3-helix
region (amino acids 102–125) and thereby permit centrosome
localization.
In summary, these findings suggest that TIG3 accesses
various cellular locations using a variety of targeting
motifs, including a C-terminal hydrophobic region that
targets membranes and the mitochondria, and a centrosome-
localizing motif located in the N-terminal hydrophilic
domain. It appears possible that the ultimate intracellular
destination of TIG3 is determined by a change in the TIG3
structure that either hides or exposes the centrosome-localiz-
ing domain.
MATERIALS AND METHODS
Cell culture, cloning, adenovirus infection, and electroporation
SCC-13 cells were obtained from ATCC (Rockville, MD) and were
maintained in high glucose DMEM (Gibco, 11960-044) supplemen-
ted with 2 mM L-glutamine, 1 mM sodium pyruvate, 100 U ml 1
penicillin, 100mg ml 1 streptomycin, and 5% fetal bovine serum
(Sigma, St Louis, MO). TIG3 constructs were produced by amplifying
the desired sequence using primers and then cloning into pcDNA3 or
pEGFP-N1 plasmids (Clontech, Mountain View, CA) using NEB
Quick Ligase. The sequence of each plasmid was confirmed by
DNA sequencing. Adenoviruses were produced as previously described
(Sturniolo et al., 2003). tAd5-TIG3(1–164), is a tetracycline-inducible
virus that encodes the full-length TIG3 protein and a tetracycline-
responsive enhancer element (Sturniolo et al., 2005). The Ad5-TA
virus encodes the tetracycline transactivator (TA). The tAd5-TIG3(1–
134) virus encodes TIG3 protein lacking the C-terminal hydrophobic
region, and tAd5-EV is an empty virus used as a control (Sturniolo
et al., 2003, 2005). For infection, cells are washed with phosphate-
buffered saline, and incubated with 10 multiplicity of infection
(MOI) of TIG3-encoding or empty virus in the presence of 5 MOI
of Ad5-TA in DMEM containing 6mg polybrene ml 1 (Sigma,
H9268). After 5 hours, the medium is replaced with virus-free
medium and incubation is continued for an additional 24 hours
before the preparation of cells and extracts for cell count,
immunocytochemistry, and immunoblot. For delivery of DNA by
electroporation, cells were treated with 3mg of plasmid using a Lonza
Nucleofector II device and human keratinocyte nucleofector kit. Cells
were incubated for 24–48 hour post electroporation before fixation
and immunostaining.
Immunological methods
Extracts for immunoblot were prepared in 20 mM Tris- HCl, pH 7.5,
lysis buffer containing 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1%
Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM glycerophosphate,
1 mM sodium vanadate, 1mg ml 1 leupeptin (Cell Signaling, 9803,
Danvers, MA), and 1 mM phenylmethylsulfonyl fluoride. Equal
amounts of protein were electrophoresed on Ready Gels (Bio-Rad,
Hercules, CA) and transferred to nitrocellulose membranes for
immunoblot. For immunofluorescence, cells maintained on cover-
slips were infected with adenoviruses or electroporated with plasmid.
After 24–48 hours, the cells were fixed in 4% paraformaldehyde,
permeabilized with methanol, and incubated with organelle marker-
specific antibody, followed by Alexa Fluor 488–conjugated goat
anti-rabbit IgG (1:1,000) or Alexa Fluor 555–conjugated goat
anti-mouse IgG (1:1,000) secondary antibody. Cells were then
incubated with Hoechst 33258 (1:2,000), washed thoroughly, and
mounted on slides using Fluoromount (Sigma, F4680). Confocal cell
images were generated using an Olympus IX81 spinning disk
confocal microscope.
Antibodies and reagents
Polyclonal rabbit anti-TIG3 production was as previously described
(Sturniolo et al., 2003, 2005; Jans et al., 2008). b-actin (A1978) and
FLAG-M2-Cy3 (A9594) antibodies were purchased from Sigma (St
Louis, MO). Caspase 3 (9665), Caspase 9 (9502), and cleaved PARP
(9541) antibodies were obtained from Cell Signaling (Danvers, MA).
GM130 (610822) and calnexin (610524) antibodies were purchased
from BD Transduction Laboratories (San Jose, CA). Pericentrin
(ab28144) antibody was from Abcam (Cambridge, MA). GFP
antibody (sc-8334) was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). Alexa Fluor 488–conjugated goat anti-rabbit (A-
11034), Alexa Fluor 555–conjugated goat anti-mouse (A-21424),
Hoechst 33258 (H3569), and MitoTracker Red CMXRos (M7512)
were from Invitrogen (Carlsbad, CA). Rabbit horseradish peroxidase
(HRP)–conjugated IgG (NA934) and mouse HRP–conjugated IgG
(NXA931) were from GE Healthcare (Piscataway, NJ). Cells were
incubated with 200 nm MitoTracker Red CMXRos for 30 minutes
before fixation.
FLAG immunohistochemistry
To monitor FLAG-tagged TIG3 mutant expression, SCC-13 cells,
grown on coverslips, were washed twice with TBS, and then fixed
in 3% paraformaldehyde þ 0.5% Triton X-100. The cells were
washed in TBS four times, blocked in 10% goat serum, and then
incubated with the Cy3-conjugated FLAG antibody for 1 hour.
Apoptosis assay: detection of cleaved PARP
SCC-13 cells (1.2 million) were transfected with 3mg of plasmid
encoding FLAG-tagged TIG3 proteins and plated on glass coverslips.
After 48 hours, the cells were fixed and co-stained with anti-FLAG
and anti-cleaved PARP. The cells were imaged using confocal
microscopy and the percentage of FLAG-positive cells that were
cleaved PARP-positive was determined as an index of the ability of
each protein to induce apoptosis.
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